StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) stock

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$584.10−3.78 (-0.64%)

Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –

United Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

United Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $1.69B, up 22.9% year over year. For fiscal 2025 it was $1.56B, up 17.6% from the year before. Over ten years it grew 15.1% a year on average. The highest annual figure on record is $1.56B in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.56B+17.6%
FY2024Dec 31, 2024$1.33B+35.7%
FY2023Dec 31, 2023$978.00M+21.9%
FY2022Dec 31, 2022$802.50M+34.2%
FY2021Dec 31, 2021$598.20M-20.8%
FY2020Dec 31, 2020$755.70M–
FY2019Dec 31, 2019-$206.60M-126.5%
FY2018Dec 31, 2018$778.40M+64.2%
FY2017Dec 31, 2017$474.20M-26.3%
FY2016Dec 31, 2016$643.60M+68.1%
FY2015Dec 31, 2015$382.80M+7.7%
FY2014Dec 31, 2014$355.30M-16.5%
FY2013Dec 31, 2013$425.27M+31.4%
FY2012Dec 31, 2012$323.63M+29.4%
FY2011Dec 31, 2011$250.20M+18.3%
FY2010Dec 31, 2010$211.53M+112.1%
FY2009Dec 31, 2009$99.72M–
FY2008Dec 31, 2008-$40.43M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$313.60M+63.6%
Q1 FY2026Mar 31, 2026$463.30M+0.5%
Q4 FY2025Dec 31, 2025$346.20M+1.5%
Q3 FY2025Sep 30, 2025$562.10M+49.0%
Q2 FY2025Jun 30, 2025$191.70M-17.4%
Q1 FY2025Mar 31, 2025$461.20M+22.5%
Q4 FY2024Dec 31, 2024$341.20M+126.4%
Q3 FY2024Sep 30, 2024$377.20M+9.0%
Q2 FY2024Jun 30, 2024$232.20M+118.4%
Q1 FY2024Mar 31, 2024$376.50M+0.5%
Q4 FY2023Dec 31, 2023$150.70M+17.6%
Q3 FY2023Sep 30, 2023$346.20M+33.9%
Q2 FY2023Jun 30, 2023$106.30M-16.3%
Q1 FY2023Mar 31, 2023$374.80M+29.8%
Q4 FY2022Dec 31, 2022$128.20M-26.6%
Q3 FY2022Sep 30, 2022$258.60M+39.3%
Q2 FY2022Jun 30, 2022$127.00M-14.3%
Q1 FY2022Mar 31, 2022$288.70M+221.5%
Q4 FY2021Dec 31, 2021$174.60M+38.4%
Q3 FY2021Sep 30, 2021$185.60M-26.0%
Q2 FY2021Jun 30, 2021$148.20M-9.6%
Q1 FY2021Mar 31, 2021$89.80M-58.2%
Q4 FY2020Dec 31, 2020$126.20M+23.1%
Q3 FY2020Sep 30, 2020$250.90M+35.3%
Q2 FY2020Jun 30, 2020$164.00M+23.4%
Q1 FY2020Mar 31, 2020$214.60M–
Q4 FY2019Dec 31, 2019$102.50M+20.0%
Q3 FY2019Sep 30, 2019$185.40M-21.9%
Q2 FY2019Jun 30, 2019$132.90M-26.1%
Q1 FY2019Mar 31, 2019-$627.40M-327.6%
Q4 FY2018Dec 31, 2018$85.40M–
Q3 FY2018Sep 30, 2018$237.50M-8.1%
Q2 FY2018Jun 30, 2018$179.80M+154.3%
Q1 FY2018Mar 31, 2018$275.70M+19.5%
Q4 FY2017Dec 31, 2017-$85.80M-152.5%
Q3 FY2017Sep 30, 2017$258.50M+13.0%
Q2 FY2017Jun 30, 2017$70.70M–
Q1 FY2017Mar 31, 2017$230.80M–
Q4 FY2016Dec 31, 2016$163.40M–
Q3 FY2016Sep 30, 2016$228.70M–

More United Therapeutics figures

See a number that looks wrong?